| P2093 | author name string | David E Geller | |
| | Susan Madge | |
| P2860 | cites work | Personal Construct Psychology: A Theory to Help Understand Professional Development, A Philosophy to Support It | Q30394390 |
| | Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis | Q33446096 |
| | Adherence with tobramycin inhaled solution and health care utilization | Q33798682 |
| | The changing microbial epidemiology in cystic fibrosis | Q33825634 |
| | Total deposition of therapeutic particles during spontaneous and controlled inhalations | Q73819765 |
| | A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study | Q80403102 |
| | Treatment compliance in children and adults with cystic fibrosis | Q80785427 |
| | Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? | Q82214146 |
| | Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis | Q83352572 |
| | Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa | Q83797983 |
| | A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis | Q84213052 |
| | Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects | Q85115976 |
| | Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial | Q33861117 |
| | Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial | Q33957168 |
| | Child and parent perceptions of monitoring in chronic illness management: a qualitative study | Q34065129 |
| | Clinical significance of microbial infection and adaptation in cystic fibrosis | Q34491552 |
| | Determinants of adherence in adults with cystic fibrosis | Q34616202 |
| | Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus | Q34658732 |
| | Longitudinal association between medication adherence and lung health in people with cystic fibrosis. | Q35042866 |
| | The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future | Q35049717 |
| | Adherence intervention research: what have we learned and what do we do next? | Q35298348 |
| | Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 |
| | Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research | Q35743037 |
| | Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence | Q36013046 |
| | Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician | Q36559804 |
| | Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper | Q36594266 |
| | Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. | Q36924692 |
| | High treatment burden in adults with cystic fibrosis: challenges to disease self-management | Q37187487 |
| | Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection | Q37333170 |
| | Aerosol antibiotics in cystic fibrosis. | Q37459094 |
| | Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology | Q37851986 |
| | Health policy, patient-centred care and clinical ethics | Q37915607 |
| | Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis | Q39286989 |
| | Psychological and educational factors: better predictors of work status than FEV1 in adults with cystic fibrosis. | Q40477419 |
| | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis | Q42017846 |
| | Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety | Q42163306 |
| | Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers | Q42603342 |
| | Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis | Q43256983 |
| | Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis | Q43299351 |
| | Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project | Q43426306 |
| | Perspective In Parental Coping With A Chronically Ill Child: The Case Of Cystic Fibrosis | Q44200896 |
| | Adherence monitoring in drug delivery | Q45882277 |
| | Shifting patterns of inhaled antibiotic use in cystic fibrosis | Q46453908 |
| | Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT. | Q47224489 |
| | Controlled inhalation of aerosolised therapeutics | Q47689004 |
| | Medical compliance and coping with cystic fibrosis | Q48963767 |
| | Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. | Q51089782 |
| | Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. | Q51092025 |
| | Adherence and competence assessment in studies of CBT for psychosis: current status and future directions. | Q51698193 |
| | Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. | Q52846177 |
| | Efficacy of aerosolized tobramycin in patients with cystic fibrosis. | Q54237890 |
| | Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it | Q58422151 |
| | Noncompliance and treatment failure in children with asthma | Q71930915 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | S24-31 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Respiratory Medicine | Q2659932 |
| P1476 | title | Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis | |
| P478 | volume | 105 Suppl 2 | |